Citadel Advisors’s Actuate Therapeutics ACTU Stock Holding History

Citadel Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,185	Closed	-$96K	–	15594
2025 Q1	$96K	Buy	+14,185	New	+$114K	﹤0.01%	11534

Other funds holding ACTU

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

Citadel Advisors's ACTU Position: Q2 2025 in Review

Citadel Advisors sold out of Actuate Therapeutics (ACTU) in Q2 2025, closing a stake of 14,185 shares — an estimated $96K sold.

Citadel Advisors first reported a position in ACTU in Q1 2025 and held it in 1 quarter. The position peaked at $96K in Q1 2025. 38 funds tracked by Wall St. Rank hold ACTU as of Q2 2025.

Citadel Advisors reported no remaining Actuate Therapeutics position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 14,185 Actuate Therapeutics shares in Q2 2025, an estimated $96K.
Citadel Advisors first reported a position in Actuate Therapeutics in Q1 2025 and held it in 1 quarter.
Citadel Advisors's Actuate Therapeutics position peaked at $96K in Q1 2025.
38 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.